Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript October 31, 2024Syros Pharmaceuticals, Inc. beats earnings expectations.
Posts Tagged ‘NASDAQ:SYRS’
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Syros Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2024 Earnings Call Transcript
Operator: Good morning and welcome to Syros Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript
Operator: Good morning and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to Syros Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Syros Pharmaceuticals' Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen only mode.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Syros Pharmaceuticals' First Quarter 2023 Financial Results Conference Call. [Operator Instructions].
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call.
5 Best One Dollar Stocks To Buy Now
In this article, we discuss the 5 best one dollar stocks to buy today.
Cathie Wood is Dumping These 15 Stocks
In this article, we discuss the 15 stocks Cathie Wood is dumping.
Were Hedge Funds Right About Syros Pharmaceuticals, Inc. (SYRS)?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great...
Is SYRS A Good Stock To Buy Now?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Hedge Funds Are Selling Syros Pharmaceuticals, Inc. (SYRS)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file ...
Hedge Funds Are Dumping Syros Pharmaceuticals, Inc. (SYRS)
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics ...
Were Hedge Funds Right About Snapping Up Syros Pharmaceuticals, Inc. (SYRS)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th.
Is Syros Pharmaceuticals Inc (SYRS) A Good Stock To Buy?
You probably know from experience that there is not as much information on small-cap companies as there is on large companies.
Baker Bros. Opened Positions In These 5 Healthcare Stocks
Julian Baker and Felix Baker founded Baker Bros. Advisors in 2000.
5 Stocks That Healthcare Fund Deerfield Management Was Buying in Q2
Founded by James E. Flynn in 2000, Deerfield Management has grown to become one of the premier healthcare-focused investment management companies today.
10 Battered Biotech Stocks That Hit 52-Week Lows Friday
The markets have been strong over the past two weeks, bucking expectations that Britain's exit from the European Union would lead to a medium-term malaise in the market.
Syros Pharmaceuticals (SYRS): Deerfield Management Discloses Position
James E. Flynn's Deerfield Management has disclosed a stake in Syros Pharmaceuticals Inc (NASDAQ:SYRS), a biotechnology company recently gone public.
